» Articles » PMID: 34405988

Comparison Between Fluorescence Imaging and Elemental Analysis to Determine Biodistribution of Inorganic Nanoparticles with Strong Light Absorption

Overview
Date 2021 Aug 18
PMID 34405988
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Black porous silicon nanoparticles (BPSi NPs) are known as highly efficient infrared light absorbers that are well-suitable for photothermal therapy (PTT) and photoacoustic imaging (PAI). PTT and PAI require a sufficient number of effectively light-absorbing NPs to be accumulated in tumor after intravenous administration. Herein, biodistribution of PEGylated BPSi NPs with different sizes (i.e., 140, 200, and 300 nm in diameter) is investigated after intravenous administration in mice. BPSi NPs were conjugated with fluorescent dyes Cy5.5 and Cy7.5 to track them and , respectively. Optical imaging with an imaging system (IVIS) was found to be an inadequate technique to assess the biodistribution of the dye-labeled BPSi NPs because the intrinsic strong absorbance of the BPSi NPs interfered fluorescence detection. This challenge was resolved via the use of inductively coupled plasma optical emission spectrometry to analyze the silicon content in different tissues and tumors. The results indicated that most of the polyethylene glycol-coated BPSi NPs were found to accumulate in the liver and spleen after intravenous injection. The smallest 140 nm particles accumulated the most in tumors at an amount of 9.5 ± 3.4% of the injected dose (concentration of 0.18 ± 0.08 mg/mL), the amount known to produce sufficient heat for cancer PTT. Furthermore, the findings from the present study also suggest that techniques other than optical imaging should be considered to study the organ biodistribution of NPs with strong light absorbance properties.

Citing Articles

A synthetic cyclic peptide for promoting antigen presentation and immune activation.

Zhang J, Madge H, Mahmoud A, Lu L, Wang W, Huang W NPJ Vaccines. 2025; 10(1):9.

PMID: 39809901 PMC: 11733015. DOI: 10.1038/s41541-024-01050-4.


Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer.

Wen H, Poutiainen P, Batnasan E, Latonen L, Lehto V, Xu W Pharmaceutics. 2023; 15(10).

PMID: 37896267 PMC: 10610067. DOI: 10.3390/pharmaceutics15102507.


Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting.

Han S, Wang J, Yavuz E, Zam A, Rouatbi N, Utami R J Control Release. 2023; 357:606-619.

PMID: 37061195 PMC: 10390340. DOI: 10.1016/j.jconrel.2023.04.022.


Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.

Yang J, Luly K, Green J Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022; 15(2):e1853.

PMID: 36193561 PMC: 10023321. DOI: 10.1002/wnan.1853.

References
1.
Tamarov K, Nakki S, Xu W, Lehto V . Approaches to improve the biocompatibility and systemic circulation of inorganic porous nanoparticles. J Mater Chem B. 2020; 6(22):3632-3649. DOI: 10.1039/c8tb00462e. View

2.
Salonen J, Laitinen L, Kaukonen A, Tuura J, Bjorkqvist M, Heikkila T . Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release. 2005; 108(2-3):362-74. DOI: 10.1016/j.jconrel.2005.08.017. View

3.
Bazak R, Houri M, El Achy S, Kamel S, Refaat T . Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2014; 141(5):769-84. PMC: 4710367. DOI: 10.1007/s00432-014-1767-3. View

4.
Decuzzi P, Godin B, Tanaka T, Lee S, Chiappini C, Liu X . Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2009; 141(3):320-7. DOI: 10.1016/j.jconrel.2009.10.014. View

5.
Nakki S, Rytkonen J, Nissinen T, Florea C, Riikonen J, Ek P . Improved stability and biocompatibility of nanostructured silicon drug carrier for intravenous administration. Acta Biomater. 2014; 13:207-15. DOI: 10.1016/j.actbio.2014.11.019. View